Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
29 November 2023 - 10:06PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2023
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
November 29, 2023
2
Exhibit 99.1
ASX ANNOUNCEMENT |
29 November 2023 |
Notice Under Section 708A(5)(e)
of the Corporations Act
This notice is given by Alterity
Therapeutics Limited ACN 080 699 065 (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), under section 708A(5)(e)
of the Corporations Act 2001 (Cth) (Corporations Act).
Details of securities issued |
|
Type |
Shares |
Class/Description |
Fully paid ordinary shares |
ASX Code |
ATH |
Date of Issue |
29 November 2023 |
Number Issued |
362,462,762 |
The Company gives notice pursuant to
section 708A(5)(e) of the Corporations Act that:
| 1. | the Company issued the Shares without disclosure under Part
6D.2 of the Corporations Act; |
| 2. | as at the date of this notice, the Company has complied with: |
| (i) | the provisions of Chapter 2M of the Corporations Act as they
apply to the Company; and |
| (ii) | sections 674 and 674A of the Corporations Act; and |
| 3. | as at the date of this notice there is no information to
be disclosed which is ‘excluded information’ (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is
required to be disclosed by the Company. |
Phillip Hains
Company Secretary
Alterity Therapeutics Limited ACN
080 699 065
Level 3, 62 Lygon Street Carlton
Victoria 3053 Australia
www.alteritytherapeutics.com
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
Historical Stock Chart
From Sep 2023 to Sep 2024